Psychometric properties of patient-reported outcome measures for health-related quality of life in multiple myeloma: a systematic review based on COSMIN guidelines Authors: Lili Xie, Qiong Feng, Jiaxin Wang, Weiyi Qin, Yuhong Ding, Zhishui Wu Published: 2026 ABSTRACT PurposeTo systematically identify patient-reported outcome measures (PROMs) used to assess health-related quality of life (HRQoL), symptoms, and disease burden in patients with multiple myeloma (MM), and to appraise their measurement properties using the COSMIN methodology.MethodsA systematic review was conducted in accordance with the COSMIN guideline for reviews of PROMs. Eligible studies reported PROM development, content validation, cross-cultural adaptation, or one or more measurement properties of PROMs used in adult patients with MM. Methodological quality was assessed using the COSMIN Risk of Bias checklist. The results for each measurement property were rated against the COSMIN criteria for good measurement properties, and the certainty of evidence was graded using the modified GRADE approach recommended by COSMIN.ResultsTwenty-six studies involving 14 PROMs were included. The EORTC QLQ-MY20 was the most frequently evaluated MM-specific module, followed by MyPOS, HM-PRO, MDASI-MM, FACT-MM, MySIm-Q, and QLICP-MM. Evidence was most often available for internal consistency, structural validity, and hypothesis testing for construct validity. By contrast, formal evidence on measurement error, criterion validity, and cross-cultural validity was seldom reported. No PROM demonstrated uniformly high-quality evidence across all key measurement properties. The EORTC QLQ-MY20 and MyPOS showed the broadest body of supportive evidence and appear to be the most defensible options for MM-specific HRQoL assessment, although additional high-quality content validity and longitudinal measurement studies remain necessary.ConclusionCurrent evidence supports the use of several MM-specific PROMs, particularly the EORTC QLQ-MY20 and MyPOS, but the overall evidence base remains uneven. Future research should prioritize patient-centered content validation, measurement-error evidence, cross-cultural validity, responsiveness, and interpretability to strengthen PROM selection for MM clinical trials and practice.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16341-3. Introduction Multiple Myeloma (MM) is the second most common hematologic malignancy, characterized by the clonal proliferation of plasma cells in the bone marrow [1]. With the widespread application of novel therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, the survival of MM patients has significantly improved, transforming the disease pattern into a chronic condition requiring long-term management [2, 3]. However, the disease itself and its treatment are often accompanied by a constellation of symptoms, including bone pain, anorexia, fatigue, increased infection risk, renal impairment, and peripheral neuropathy. These factors collectively exert a profound impact on patients’ physical function, psychological state, and social roles, leading to a significant decline in Health-Related Quality of Life (HRQoL) [4, 5]. Therefore, a comprehensive and accurate assessment of HRQoL in MM patients is of critical clinical importance for optimizing individualized treatment decisions, evaluating the net benefit of therapeutic regimens, and improving the long-term survivorship experience. Patient-Reported Outcomes (PROMs) are reports coming directly from patients about their health status and treatment, without interpretation by healthcare professionals or others [6]. In MM clinical practice and research, PROMs have become central instruments for assessing symptom burden, treatment toxicity, and HRQoL. They can capture patients’ subjective experiences that are difficult to reflect through clinical examination or laboratory parameters, facilitate doctor-patient communication, enable early identification of unmet needs, and ultimately enhance the quality of patient-centered care [7, 8]. Professional bodies such as the International Myeloma Working Group (IMWG) and the European Society for Medical Oncology (ESMO) recommend integrating PROMs into routine MM management and clinical trials [9, 10]. Currently, a variety of PROMs are used to assess quality of life in MM patients, primarily falling into two categories: generic and disease-specific instruments. Generic HRQoL instruments, applicable to the general population, cancer patients, or those with hematologic malignancies, include the Medical Outcome Study Short Form 36 (SF-36) [11], the Quality of Life Questionnaire Core 30 (QLQ-C30) [12], the EQ-5D-5 L [13], and the Hematological Malignancy Patient-Reported Outcome measure (HM-PRO) [14]. Disease-specific instruments are designed specifically for MM patients, such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma Module (EORTC QLQ-MY20) [15] and the Functional Assessment of Cancer Therapy – Multiple Myeloma (FACT-MM) [16], the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) [17], the Quality of Life Instruments for Cancer Patients with Multiple Myeloma (QLICP-MM) [18], the Myeloma Patient Outcome Scale (MyPOS) [19], and the M.D. Anderson Symptom Inventory – Multiple Myeloma Module (MDASI-MM) [20]. Additionally, several cancer symptom-focused instruments, like the Functional Assessment of Cancer Therapy – General (FACT-G) [21], the Memorial Symptom Assessment Scale (MSAS) [22], its Short Form (MSAS-SF) [23], and the Edmonton Symptom Assessment System (ESAS) [24], are also frequently employed in the MM population. Despite the availability of numerous tools, the psychometric properties of these instruments in the MM patient population have not been systematically summarized and compared. The methodological quality of instrument development and validation processes varies across studies, posing challenges for clinicians and researchers in selecting the most appropriate and robust measurement instruments. The Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) initiative provides a rigorous methodological framework for systematically reviewing the measurement properties of PROMs and the methodological quality of their studies, offering evidence-based graded recommendations for instrument selection [25, 26]. In this context, and to provide clear guidance for clinical practice and research, there is an urgent need to comprehensively evaluate existing HRQoL instruments used in MM patients employing the COSMIN methodology. This systematic review aims to: (1) systematically identify and evaluate PROMs developed or validated for MM patients; (2) critically appraise the methodological quality of evidence for these instruments’ various psychometric properties (e.g., content validity, structural validity, reliability, responsiveness); (3) synthesize the body of evidence to provide clear, evidence-based recommendations for instrument selection under different measurement purposes. Through this work, we aim to promote the standardization and scientific rigor of HRQoL assessment in MM, ultimately benefiting patient care and clinical research. Methods Design This systematic review was conducted according to the COSMIN methodology for systematic reviews of PROMs. The review focused on PROMs that had been developed, adapted, translated, or psychometrically evaluated for use in patients with MM [25, 27]. Throughout the manuscript, the term “PROM” or “instrument” is used rather than “scale”, unless a specific instrument is formally named as an instrument. The study protocol was registered prospectively in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD420251127878). Reporting will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) – COSMIN Extension statement [28]. Search strategy A systematic search was performed across eight databases: PubMed, Web of Science, Embase, CINAHL, Cochrane Library, SinoMed, China National Knowledge Infrastructure, and Wanfang Data. The search covered studies published from the inception of each database until August 26, 2025. References of included studies were also tracked. The search strategy combined Medical Subject Headings (MeSH) terms, keywords, and search filters [29] to identify studies related to measurement properties. Detailed search strategies for all databases are provided in Supplementary S3. Eligibility criteria Studies were eligible if they reported the development, content validation, cross-cultural adaptation, or evaluation of at least one measurement property of a PROM used to assess HRQoL, symptoms, functioning, disease burden, or treatment-related impact in adults with MM. Eligible instruments included MM-specific PROMs and broader cancer-, hematology-, or generic HRQoL instruments when they were evaluated in an MM population or were commonly used as comparator or companion measures in MM studies. Studies were excluded if they were not published in English or Chinese; were secondary literature, such as reviews, systematic reviews, meta-analyses, conference abstracts, commentaries, or books; had no available full text; reported duplicate data; or reported only clinical outcomes without PROM measurement-property evidence. Study selection Two reviewers familiar with the COSMIN guidelines and evidence-based medicine independently performed the literature screening. First, duplicate records were removed using the reference management software EndNote X20. Subsequently, titles and abstracts were screened to exclude obviously irrelevant studies. The full texts of the remaining records were read to determine final inclusion. If no validation study in MM patients was retrieved for a specific instrument, its original publication or landmark validation study was traced and included to assess the instruments’ basic psychometric properties. Disagreements during screening were resolved through discussion with a third senior methodological researcher. The entire screening process and reasons for exclusion were documented. Data extraction and analysis For each included study, two reviewers independently extracted publication details, country and language, PROM name, target construct, target population, sample size, item number, response options, recall period, scoring method, and all reported measurement properties. Extracted measurement properties were mapped to the COSMIN taxonomy: PROM development, content validity, structural validity, internal consistency, cross-cultural validity/measurement invariance, reliability, measurement error, criterion validity, hypothesis testing for construct validity, and responsiveness. Methodological quality assessment Methodological quality was evaluated with the COSMIN Risk of Bias checklist [27]. Each study was assessed separately for each measurement property that it reported. The PROM development box and the content validity box were judged independently, because they address different evidence sources: the adequacy of the instrument-development process and the quality of studies evaluating relevance, comprehensiveness, and comprehensibility. Each box was rated as very good, adequate, doubtful, or inadequate using the COSMIN “worst score counts” principle. Evaluation of psychometric property The results for each measurement property were rated as sufficient (+), insufficient (−), or indeterminate (?) using the COSMIN criteria for good measurement properties [27, 30, 31]. For example, internal consistency was considered sufficient when Cronbach’s alpha was ≥ 0.70 and structural validity for the corresponding instrument or subscale was at least supported [27]. Reliability was considered sufficient when the intraclass correlation coefficient or weighted kappa was ≥ 0.70 [27]. Hypothesis testing for construct validity and responsiveness were considered sufficient when at least 75% of predefined or review-team hypotheses were confirmed [27]. Content validity was summarized across relevance, comprehensiveness, and comprehensibility, while distinguishing evidence from PROM-development studies from evidence from additional content-validity studies [27]. Evidence synthesis and grading For each PROM and measurement property, the certainty of evidence was graded as high, moderate, low, or very low using the modified GRADE approach recommended by COSMIN, taking into account methodological quality, inconsistency, imprecision, and indirectness [25, 27]. Final recommendations were categorized as follows [25, 27]: category A, PROMs with evidence for sufficient content validity and at least low-quality evidence for sufficient internal consistency; category B, PROMs with potential for use but requiring further validation; and category C, PROMs with high-quality evidence for an insufficient measurement property and therefore not recommended for the target context. Results Study selection A total of 3633 records were initially identified (Fig. 1). After removing 597 duplicates and 18 ineligible records, 3018 records were screened. Title screening excluded 2775 records. Abstract review of 243 records led to the exclusion of 145. Full-text assessment of 98 articles resulted in the selection of 20 articles based on eligibility criteria. An additional 6 articles were identified through manual searches, culminating in 26 articles [18, 32–56] included in the systematic review of quality of life in multiple myeloma patients. Fig. 1PRISMA flow diagram illustrating screening and selection of articles PRISMA flow diagram illustrating screening and selection of articles Study characteristics After screening, 26 studies were included in the review. The included studies covered 14 PROMs relevant to MM, including MM-specific measures, hematological malignancy measures, cancer-specific measures, symptom measures, and generic HRQoL instruments. The most frequently studied MM-specific instrument was the EORTC QLQ-MY20, which had been evaluated in multiple languages and cultural contexts. Other MM-relevant instruments included MyPOS, FACT-MM, MDASI-MM, MySIm-Q, QLICP-MM, and HM-PRO. Generic or broader oncology instruments included the EORTC QLQ-C30, FACT-G, MSAS, MSAS-SF, ESAS, EQ-5D-5 L, and SF-36. Study characteristics are summarized in Table 1. Table 1Characteristics of included studiesPROMYearStudyCountry/languagePurposeSample/target populationMeasurement properties addressedEORTC QLQ-MY202007K Cocks [32]International/EnglishDevelopment and field testing of an MM moduleAdults with MM; international field-test samplePROM development, content validity, structural validity, internal consistency, construct validity, responsivenessEORTC QLQ-MY202012Kontodimopoulos, N. [33]Greece/GreekTranslation and validationGreek patients with MMStructural validity, internal consistency, reliability, construct validityEORTC QLQ-MY202015Espinoza-Zamora, J. R [34]Mexico/SpanishCultural adaptation and validationMexican patients with MMInternal consistency, test–retest reliability, construct validity, responsivenessEORTC QLQ-MY202016Ahmadzadeh, A. [35]Iran/PersianTranslation and validationPersian-speaking patients with MMInternal consistency, reliability, construct validityEORTC QLQ-MY202023Dachs, L. R. [36]Brazil/PortugueseValidation in Brazilian PortugueseBrazilian patients with MMInternal consistency; hypothesis testing for construct validity, including known-groups comparisonsEORTC QLQ-MY202024Lorca, L. A. [37]Chile/SpanishValidation in Chilean SpanishChilean patients with MMInternal consistency, construct validityEORTC QLQ-MY202025Chao Liu [38]China/ChineseTranslation and psychometric validationChinese patients with MMContent validity, structural validity, internal consistency, reliability, construct validityMyPOS2015Osborne, T. R [39]United Kingdom/EnglishDevelopment and validationPatients with MM across clinical settingsPROM development, content validity, structural validity, internal consistency, reliability, construct validityMyPOS2017Ramsenthaler, C. [40]United Kingdom/EnglishClinical validation and responsiveness testingPatients with MM receiving careStructural validity, internal consistency, reliability, construct validity, responsivenessMyPOS2020Gerlach, C. [41]Germany/GermanTranslation and cultural adaptationGerman-speaking patients with MMCross-cultural adaptation, content validity, feasibilityFACT-MM2012Wagner, L.I. [42]United States/EnglishDevelopment of an MM-specific FACT modulePatients with MM and cliniciansPROM development, content validity, internal consistency, construct validityMDASI-MM2013Jones, D. [43]United States/EnglishDevelopment and validation of an MM symptom modulePatients with MM undergoing therapy or transplantationPROM development, structural validity, internal consistency, reliability, construct validityMDASI-MM2025Ting Wang [44]China/ChineseTranslation and validationChinese patients with MMContent validity, structural validity, internal consistency, reliability, construct validityMySIm-Q2021Gries, K. S. [45]International/EnglishDevelopment and psychometric validationPatients with MMPROM development, content validity, structural validity, internal consistency, reliability, construct validityQLICP-MM2022Li Weiqang [18]China/ChineseDevelopment and validation of an MM moduleChinese patients with MMPROM development, structural validity, internal consistency, reliability, construct validity, responsivenessHM-PRO2020Goswami, P. [46]United Kingdom/EnglishContent validationPatients with hematological malignancies including MMPROM development, content validityHM-PRO2020Goswami, P. [47]United Kingdom/EnglishPsychometric validationPatients with hematological malignancies including MMStructural validity, internal consistency, reliability, construct validityHM-PRO2025Sam Salek [48]International/multilingualFurther validation and use in hematologic malignanciesPatients with hematological malignancies including MMContent validity, construct validity, feasibilityEORTC QLQ-C301993Ringdal, G. I. [49]Norway/NorwegianCancer HRQoL validationPatients with cancer including hematological malignanciesStructural validity, internal consistency, construct validityFACT-G1993D F Cella [50]United States/EnglishDevelopment and validation of general cancer HRQoL measurePatients with cancerPROM development, content validity, internal consistency, construct validityMSAS1994R K Portenoy [51]United States/EnglishDevelopment of symptom assessment scalePatients with cancerPROM development, internal consistency, construct validityESAS2000V T Chang [52]United States/EnglishValidation of symptom assessment systemPatients with cancer or palliative-care needsReliability, construct validity, responsivenessMSAS-SF2000V T Chang [53]United States/EnglishShort-form symptom assessmentPatients with cancerInternal consistency, construct validityEQ-5D-5 L2011M Herdman [54]International/multilingualDevelopment of five-level EQ-5DGeneral and patient populationsPROM development, content validity, construct validityEQ-5D-5 L2012Seon Ha Kim [55]Korea/KoreanValidation of EQ-5D-5 LKorean general/patient sampleHypothesis testing for construct validity, including known-groups comparisons; feasibilitySF-361992J E Brazier [56]United Kingdom/EnglishValidation of generic health surveyGeneral population/patient samplesInternal consistency; hypothesis testing for construct validity, including known-groups comparisonsGeneric instruments were retained because they are commonly used as comparator or companion measures but were not interpreted as MM-specific PROMsPROM patient-reported outcome measure, MM multiple myeloma, HRQoL health-related quality of life Table 1Characteristics of included studiesPROMYearStudyCountry/languagePurposeSample/target populationMeasurement properties addressedEORTC QLQ-MY202007K Cocks [32]International/EnglishDevelopment and field testing of an MM moduleAdults with MM; international field-test samplePROM development, content validity, structural validity, internal consistency, construct validity, responsivenessEORTC QLQ-MY202012Kontodimopoulos, N. [33]Greece/GreekTranslation and validationGreek patients with MMStructural validity, internal consistency, reliability, construct validityEORTC QLQ-MY202015Espinoza-Zamora, J. R [34]Mexico/SpanishCultural adaptation and validationMexican patients with MMInternal consistency, test–retest reliability, construct validity, responsivenessEORTC QLQ-MY202016Ahmadzadeh, A. [35]Iran/PersianTranslation and validationPersian-speaking patients with MMInternal consistency, reliability, construct validityEORTC QLQ-MY202023Dachs, L. R. [36]Brazil/PortugueseValidation in Brazilian PortugueseBrazilian patients with MMInternal consistency; hypothesis testing for construct validity, including known-groups comparisonsEORTC QLQ-MY202024Lorca, L. A. [37]Chile/SpanishValidation in Chilean SpanishChilean patients with MMInternal consistency, construct validityEORTC QLQ-MY202025Chao Liu [38]China/ChineseTranslation and psychometric validationChinese patients with MMContent validity, structural validity, internal consistency, reliability, construct validityMyPOS2015Osborne, T. R [39]United Kingdom/EnglishDevelopment and validationPatients with MM across clinical settingsPROM development, content validity, structural validity, internal consistency, reliability, construct validityMyPOS2017Ramsenthaler, C. [40]United Kingdom/EnglishClinical validation and responsiveness testingPatients with MM receiving careStructural validity, internal consistency, reliability, construct validity, responsivenessMyPOS2020Gerlach, C. [41]Germany/GermanTranslation and cultural adaptationGerman-speaking patients with MMCross-cultural adaptation, content validity, feasibilityFACT-MM2012Wagner, L.I. [42]United States/EnglishDevelopment of an MM-specific FACT modulePatients with MM and cliniciansPROM development, content validity, internal consistency, construct validityMDASI-MM2013Jones, D. [43]United States/EnglishDevelopment and validation of an MM symptom modulePatients with MM undergoing therapy or transplantationPROM development, structural validity, internal consistency, reliability, construct validityMDASI-MM2025Ting Wang [44]China/ChineseTranslation and validationChinese patients with MMContent validity, structural validity, internal consistency, reliability, construct validityMySIm-Q2021Gries, K. S. [45]International/EnglishDevelopment and psychometric validationPatients with MMPROM development, content validity, structural validity, internal consistency, reliability, construct validityQLICP-MM2022Li Weiqang [18]China/ChineseDevelopment and validation of an MM moduleChinese patients with MMPROM development, structural validity, internal consistency, reliability, construct validity, responsivenessHM-PRO2020Goswami, P. [46]United Kingdom/EnglishContent validationPatients with hematological malignancies including MMPROM development, content validityHM-PRO2020Goswami, P. [47]United Kingdom/EnglishPsychometric validationPatients with hematological malignancies including MMStructural validity, internal consistency, reliability, construct validityHM-PRO2025Sam Salek [48]International/multilingualFurther validation and use in hematologic malignanciesPatients with hematological malignancies including MMContent validity, construct validity, feasibilityEORTC QLQ-C301993Ringdal, G. I. [49]Norway/NorwegianCancer HRQoL validationPatients with cancer including hematological malignanciesStructural validity, internal consistency, construct validityFACT-G1993D F Cella [50]United States/EnglishDevelopment and validation of general cancer HRQoL measurePatients with cancerPROM development, content validity, internal consistency, construct validityMSAS1994R K Portenoy [51]United States/EnglishDevelopment of symptom assessment scalePatients with cancerPROM development, internal consistency, construct validityESAS2000V T Chang [52]United States/EnglishValidation of symptom assessment systemPatients with cancer or palliative-care needsReliability, construct validity, responsivenessMSAS-SF2000V T Chang [53]United States/EnglishShort-form symptom assessmentPatients with cancerInternal consistency, construct validityEQ-5D-5 L2011M Herdman [54]International/multilingualDevelopment of five-level EQ-5DGeneral and patient populationsPROM development, content validity, construct validityEQ-5D-5 L2012Seon Ha Kim [55]Korea/KoreanValidation of EQ-5D-5 LKorean general/patient sampleHypothesis testing for construct validity, including known-groups comparisons; feasibilitySF-361992J E Brazier [56]United Kingdom/EnglishValidation of generic health surveyGeneral population/patient samplesInternal consistency; hypothesis testing for construct validity, including known-groups comparisonsGeneric instruments were retained because they are commonly used as comparator or companion measures but were not interpreted as MM-specific PROMsPROM patient-reported outcome measure, MM multiple myeloma, HRQoL health-related quality of life Characteristics of included studies Generic instruments were retained because they are commonly used as comparator or companion measures but were not interpreted as MM-specific PROMs PROM patient-reported outcome measure, MM multiple myeloma, HRQoL health-related quality of life Characteristics of included PROMs The included PROMs varied substantially in construct coverage, item number, recall period, scoring structure, and intended use. MM-specific modules, such as the EORTC QLQ-MY20, FACT-MM, MDASI-MM, MySIm-Q, and QLICP-MM, were designed to capture symptoms and impacts that are more directly relevant to MM and its treatment. MyPOS and HM-PRO covered broader palliative-care or hematological-malignancy concerns and included physical, emotional, informational, and practical domains. Generic instruments such as EQ-5D-5 L and SF-36 offer comparability across diseases but provide limited coverage of MM-specific symptoms and treatment-related burden. Instrument characteristics are presented in Table 2. Table 2Characteristics of included PROMsPROMTarget constructNo. of items / domainsRecall periodResponse/scoringMM specificityTypical useEORTC QLQ-MY20 [32–38]MM-specific symptoms and impacts20 items; disease symptoms, side effects, future perspective, body imagePast week4-point Likert; transformed to 0–100MM-specific moduleUse with EORTC QLQ-C30 in trials and observational HRQoL studiesMyPOS [39–41]MM symptoms, concerns, palliative-care needs, practical and emotional impactMulti-domain instrument; patient-centered concernsRecent days/current concernsLikert-type responses; domain/total scoringMM-specificClinical/palliative-care assessment and researchFACT-MM [42]General cancer HRQoL plus MM-specific concernsFACT-G plus MM modulePast 7 days5-point Likert; higher scores generally betterMM-specific moduleStudies aligned with the FACIT frameworkMDASI-MM [43, 44]Symptom severity and interferenceCore symptom and interference items plus MM-specific symptomsPast 24 h0–10 numeric ratingMM-specific symptom moduleSymptom-burden assessment and treatment monitoringMySIm-Q [45]MM symptoms and impactsSymptom and impact domainsRecent days/past weekLikert or numeric response options; domain scoringMM-specificClinical trials focusing on symptom impactQLICP-MM [18]Quality of life in Chinese patients with MMCore QLICP domains plus MM-specific moduleRecent periodLikert-type responses; transformed scoresMM-specific moduleChinese-language HRQoL studiesHM-PRO [46–48]Hematological malignancy symptoms, signs, and impactsPart A impact items and Part B symptom/sign itemsRecent periodLikert-type responses; part scoresHematology-specific; includes MMHematological malignancy research and clinical assessmentEORTC QLQ-C30 [49]Cancer-specific HRQoL30 items; functioning, symptoms, global healthPast week4-point and 7-point responses; 0–100 transformed scoresCancer-specific, not MM-specificCompanion measure with QLQ-MY20FACT-G [50]General cancer HRQoL27 items; physical, social/family, emotional, functional well-beingPast 7 days5-point Likert; higher scores betterCancer-specific, not MM-specificCompanion measure or framework for FACT-MMMSAS [51]Symptom prevalence, severity, frequency, and distress32 symptoms and summary indicesPast weekMixed symptom-specific response scalesGeneric cancer symptom scaleBroad symptom assessmentESAS [52]Core symptom severityCommonly 9–10 symptomsCurrent/24 hours0–10 numeric ratingGeneric symptom scaleClinical symptom screeningMSAS-SF [53]Short-form symptom burdenReduced item set and summary indicesPast weekSymptom-specific response optionsGeneric cancer symptom scaleShort symptom assessmentEQ-5D-5 L [54, 55]Generic health status/utility5 dimensions plus visual analogue scaleToday5 levels per dimension; utility index and VASGenericHealth-economic evaluation and cross-disease comparisonSF-36 [56]Generic physical and mental health36 items; 8 domains and summary scoresPast 4 weeks or acute versionDomain scores 0–100GenericCross-condition HRQoL comparisonInstrument details should be checked against the final author manuals before submission, especially recall period and scoring algorithms Table 2Characteristics of included PROMsPROMTarget constructNo. of items / domainsRecall periodResponse/scoringMM specificityTypical useEORTC QLQ-MY20 [32–38]MM-specific symptoms and impacts20 items; disease symptoms, side effects, future perspective, body imagePast week4-point Likert; transformed to 0–100MM-specific moduleUse with EORTC QLQ-C30 in trials and observational HRQoL studiesMyPOS [39–41]MM symptoms, concerns, palliative-care needs, practical and emotional impactMulti-domain instrument; patient-centered concernsRecent days/current concernsLikert-type responses; domain/total scoringMM-specificClinical/palliative-care assessment and researchFACT-MM [42]General cancer HRQoL plus MM-specific concernsFACT-G plus MM modulePast 7 days5-point Likert; higher scores generally betterMM-specific moduleStudies aligned with the FACIT frameworkMDASI-MM [43, 44]Symptom severity and interferenceCore symptom and interference items plus MM-specific symptomsPast 24 h0–10 numeric ratingMM-specific symptom moduleSymptom-burden assessment and treatment monitoringMySIm-Q [45]MM symptoms and impactsSymptom and impact domainsRecent days/past weekLikert or numeric response options; domain scoringMM-specificClinical trials focusing on symptom impactQLICP-MM [18]Quality of life in Chinese patients with MMCore QLICP domains plus MM-specific moduleRecent periodLikert-type responses; transformed scoresMM-specific moduleChinese-language HRQoL studiesHM-PRO [46–48]Hematological malignancy symptoms, signs, and impactsPart A impact items and Part B symptom/sign itemsRecent periodLikert-type responses; part scoresHematology-specific; includes MMHematological malignancy research and clinical assessmentEORTC QLQ-C30 [49]Cancer-specific HRQoL30 items; functioning, symptoms, global healthPast week4-point and 7-point responses; 0–100 transformed scoresCancer-specific, not MM-specificCompanion measure with QLQ-MY20FACT-G [50]General cancer HRQoL27 items; physical, social/family, emotional, functional well-beingPast 7 days5-point Likert; higher scores betterCancer-specific, not MM-specificCompanion measure or framework for FACT-MMMSAS [51]Symptom prevalence, severity, frequency, and distress32 symptoms and summary indicesPast weekMixed symptom-specific response scalesGeneric cancer symptom scaleBroad symptom assessmentESAS [52]Core symptom severityCommonly 9–10 symptomsCurrent/24 hours0–10 numeric ratingGeneric symptom scaleClinical symptom screeningMSAS-SF [53]Short-form symptom burdenReduced item set and summary indicesPast weekSymptom-specific response optionsGeneric cancer symptom scaleShort symptom assessmentEQ-5D-5 L [54, 55]Generic health status/utility5 dimensions plus visual analogue scaleToday5 levels per dimension; utility index and VASGenericHealth-economic evaluation and cross-disease comparisonSF-36 [56]Generic physical and mental health36 items; 8 domains and summary scoresPast 4 weeks or acute versionDomain scores 0–100GenericCross-condition HRQoL comparisonInstrument details should be checked against the final author manuals before submission, especially recall period and scoring algorithms Characteristics of included PROMs Instrument details should be checked against the final author manuals before submission, especially recall period and scoring algorithms Methodological quality of included studies The methodological quality of included studies differed across measurement properties. The strongest methodological evidence was generally observed for internal consistency and structural validity when studies reported adequate sample sizes and used appropriate factor-analytic methods. Content validity evidence was less consistently reported, particularly in studies that relied primarily on expert review or psychometric field testing without detailed patient involvement. Evidence for cross-cultural validity or measurement invariance was uncommon despite the availability of translated versions of several PROMs. Measurement error and criterion validity were rarely reported. The COSMIN risk-of-bias summary is shown in Table 3. Table 3COSMIN risk-of-bias summary by PROM and measurement propertyPROMPROM developmentContent validityStructural validityInternal consistencyReliabilityMeasurement errorHypothesis testing for construct validityResponsivenessMain methodological concernsEORTC QLQ-MY20 [32–38]AdequateAdequate/limited contemporary evidenceAdequateAdequateAdequate where reportedNot adequately reportedAdequateAdequate in limited studiesOlder development evidence; limited updated content validation and measurement-error evidenceMyPOS [39–41]AdequateAdequateAdequateAdequateAdequateNot adequately reportedAdequateAdequate/limitedSome samples small or context-specific; measurement error limitedFACT-MM [42]AdequateAdequateDoubtful/limitedAdequateNot consistently reportedNot reportedAdequate/limitedNot reportedLimited independent validation and structural evidenceMDASI-MM [43, 44]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedPrimarily symptom-focused; limited responsiveness and measurement-error evidenceMySIm-Q [45]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedEvidence concentrated in development/validation contextQLICP-MM [18]Doubtful/adequateDoubtful/limitedAdequateAdequateAdequateNot reportedAdequateAdequate/limitedMainly Chinese-language evidence; limited cross-cultural evidenceHM-PRO [46–48]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedHematology-specific rather than MM-specific; MM subgroup evidence may be indirectEORTC QLQ-C30 [49]AdequateAdequate for cancer, indirect for MMAdequateAdequateAdequateLimitedAdequateAdequate in oncologyContent validity for MM-specific concerns is indirectFACT-G [50]AdequateAdequate for cancer, indirect for MMAdequateAdequateAdequateLimitedAdequateLimitedNot designed for MM-specific symptomsMSAS [51]AdequateAdequate for cancer symptoms, indirect for MMAdequateAdequateLimitedNot reportedAdequateLimitedSymptom inventory, not HRQoL-specificESAS [52]AdequateAdequate for symptom screening, indirect for MMNot applicable/limitedNot applicable/limitedAdequate/limitedLimitedAdequateAdequate/limitedScreening tool; limited multidimensional HRQoL coverageMSAS-SF [53]AdequateAdequate for cancer symptoms, indirect for MMAdequateAdequateLimitedNot reportedAdequateLimitedShort form may reduce comprehensivenessEQ-5D-5 L [54, 55]AdequateAdequate for generic health status, insufficient for MM-specific HRQoL aloneNot applicableNot applicableAdequate/limitedLimitedAdequateLimitedGeneric utility measure; content gap for MM-specific concernsSF-36 [56]AdequateAdequate for generic health, insufficient for MM-specific HRQoL aloneAdequateAdequateAdequate/limitedLimitedAdequateLimitedGeneric measure; lacks MM-specific symptom and treatment-burden contentThis table summarizes methodological quality at PROM level. In the final supplementary file, the same ratings can be expanded to study level. Known-groups comparisons were classified as one form of hypothesis testing for construct validity and were not treated as discriminant validity Table 3COSMIN risk-of-bias summary by PROM and measurement propertyPROMPROM developmentContent validityStructural validityInternal consistencyReliabilityMeasurement errorHypothesis testing for construct validityResponsivenessMain methodological concernsEORTC QLQ-MY20 [32–38]AdequateAdequate/limited contemporary evidenceAdequateAdequateAdequate where reportedNot adequately reportedAdequateAdequate in limited studiesOlder development evidence; limited updated content validation and measurement-error evidenceMyPOS [39–41]AdequateAdequateAdequateAdequateAdequateNot adequately reportedAdequateAdequate/limitedSome samples small or context-specific; measurement error limitedFACT-MM [42]AdequateAdequateDoubtful/limitedAdequateNot consistently reportedNot reportedAdequate/limitedNot reportedLimited independent validation and structural evidenceMDASI-MM [43, 44]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedPrimarily symptom-focused; limited responsiveness and measurement-error evidenceMySIm-Q [45]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedEvidence concentrated in development/validation contextQLICP-MM [18]Doubtful/adequateDoubtful/limitedAdequateAdequateAdequateNot reportedAdequateAdequate/limitedMainly Chinese-language evidence; limited cross-cultural evidenceHM-PRO [46–48]AdequateAdequateAdequateAdequateAdequateNot reportedAdequateLimited/not reportedHematology-specific rather than MM-specific; MM subgroup evidence may be indirectEORTC QLQ-C30 [49]AdequateAdequate for cancer, indirect for MMAdequateAdequateAdequateLimitedAdequateAdequate in oncologyContent validity for MM-specific concerns is indirectFACT-G [50]AdequateAdequate for cancer, indirect for MMAdequateAdequateAdequateLimitedAdequateLimitedNot designed for MM-specific symptomsMSAS [51]AdequateAdequate for cancer symptoms, indirect for MMAdequateAdequateLimitedNot reportedAdequateLimitedSymptom inventory, not HRQoL-specificESAS [52]AdequateAdequate for symptom screening, indirect for MMNot applicable/limitedNot applicable/limitedAdequate/limitedLimitedAdequateAdequate/limitedScreening tool; limited multidimensional HRQoL coverageMSAS-SF [53]AdequateAdequate for cancer symptoms, indirect for MMAdequateAdequateLimitedNot reportedAdequateLimitedShort form may reduce comprehensivenessEQ-5D-5 L [54, 55]AdequateAdequate for generic health status, insufficient for MM-specific HRQoL aloneNot applicableNot applicableAdequate/limitedLimitedAdequateLimitedGeneric utility measure; content gap for MM-specific concernsSF-36 [56]AdequateAdequate for generic health, insufficient for MM-specific HRQoL aloneAdequateAdequateAdequate/limitedLimitedAdequateLimitedGeneric measure; lacks MM-specific symptom and treatment-burden contentThis table summarizes methodological quality at PROM level. In the final supplementary file, the same ratings can be expanded to study level. Known-groups comparisons were classified as one form of hypothesis testing for construct validity and were not treated as discriminant validity COSMIN risk-of-bias summary by PROM and measurement property Adequate/ limited Doubtful/ limited Adequate/ limited Limited/ not reported Adequate/ limited Not applicable /limited Adequate/ limited This table summarizes methodological quality at PROM level. In the final supplementary file, the same ratings can be expanded to study level. Known-groups comparisons were classified as one form of hypothesis testing for construct validity and were not treated as discriminant validity Content validity Content validity was judged by considering relevance, comprehensiveness, and comprehensibility. PROMs developed specifically for MM or hematological malignancies generally had better conceptual relevance than generic HRQoL instruments. However, even among MM-specific PROMs, the depth of patient involvement and documentation of item-generation procedures varied. MyPOS, MySIm-Q, HM-PRO, and MDASI-MM provided relatively clearer evidence of patient input during development or content evaluation. The EORTC QLQ-MY20 showed broad clinical uptake and supportive validity evidence, but additional contemporary content-validation work may be needed to confirm comprehensiveness in the era of novel MM therapies. Generic instruments were considered useful as companion measures but were not judged sufficient on their own for comprehensive MM-specific HRQoL assessment. Structural validity and internal consistency Structural validity was reported for several PROMs, most often through exploratory or confirmatory factor analysis. The EORTC QLQ-MY20, MyPOS, MDASI-MM, MySIm-Q, QLICP-MM, and HM-PRO generally showed interpretable domain structures, although the level of evidence varied by study design and sample size. Internal consistency was the most frequently reported measurement property. Most multi-item domains achieved acceptable reliability coefficients, but some short domains or domains with heterogeneous content had borderline estimates. Internal consistency ratings were interpreted together with structural validity, as recommended by COSMIN. Reliability, measurement error, and responsiveness Test–retest reliability was available for only a subset of PROMs and was generally supportive when reported. However, the time interval between administrations and the evidence that patients were stable were not always sufficiently justified. Measurement-error evidence was largely unavailable, because few studies reported the standard error of measurement, smallest detectable change, limits of agreement, or minimally important change. Responsiveness was reported less frequently than internal consistency and construct validity. Where available, responsiveness evidence was mostly supportive but should be interpreted cautiously because longitudinal hypotheses and anchor-based interpretability thresholds were often incompletely specified. Hypothesis testing for construct validity Hypothesis testing for construct validity was commonly evaluated through correlations with related instruments or comparisons between clinically defined groups. In COSMIN terminology, known-groups comparisons represent one form of hypothesis testing for construct validity. Discriminant validity, in contrast, refers to evidence that PROM scores are not strongly associated with measures of different constructs. Therefore, discriminant validity was not conflated with known-groups comparisons in this review. Evidence was generally sufficient when PROM scores differed in expected directions across clinical severity, treatment status, performance status, or symptom-burden groups. Nevertheless, many studies did not clearly predefine hypotheses regarding the expected direction and magnitude of associations, which downgraded the certainty of evidence. Overall evidence and recommendations No PROM had high-certainty evidence for all key measurement properties in MM. The EORTC QLQ-MY20 had the broadest international evidence base and is the most practical MM-specific companion module when used with the EORTC QLQ-C30. MyPOS also showed relatively comprehensive evidence and may be particularly useful when palliative-care needs, symptom burden, and broader patient concerns are central outcomes. MDASI-MM and MySIm-Q are appropriate when symptom assessment is the primary objective, whereas FACT-MM and QLICP-MM may be considered when their scoring framework and language context match the study setting. Generic instruments such as EQ-5D-5 L and SF-36 are useful for health-economic evaluation or cross-condition comparison but should not be the sole PROM when MM-specific HRQoL is the main construct. The evidence synthesis and recommendations are summarized in Tables 4, 5, 6 and 7. Table 4Summary of measurement-property evidence and COSMIN recommendationsPROMContent validityStructural validityInternal consistencyReliabilityMeasurement errorCriterion validityConstruct validity / hypothesis testingResponsivenessOverall certaintyRecommendationEORTC QLQ-MY20 [32–38]+ / Low+ / Low–Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low–Moderate+ / LowLow–ModerateA: strongest current MM-specific option, but update content validity and change metricsMyPOS [39–41]+ / Moderate+ / Low+ / Low–Moderate+ / Low? / Very low? / Very low+ / Low+ / LowLow–ModerateA: suitable when broad patient concerns and palliative-care needs are centralFACT-MM [42]+ / Low? / Very low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: promising but needs independent structural, reliability, and responsiveness evidenceMDASI-MM [43, 44]+ / Low–Moderate+ / Low+ / Low–Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: appropriate for MM symptom burden, not stand-alone HRQoLMySIm-Q [45]+ / Moderate+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: useful for symptom-impact endpoints; further independent validation and change-metric studies neededQLICP-MM [18]? / Low+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low+ / LowLowB: potentially useful in Chinese contexts; cross-cultural evidence neededHM-PRO [46–48]+ / Low–Moderate+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: useful for hematological malignancies; MM-specific evidence indirectEORTC QLQ-C30 [49]+ / Moderate for cancer; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low+ / LowModerate for cancer; low for MM specificityB: companion measure; not sufficient alone for MM-specific HRQoLFACT-G [50]+ / Moderate for cancer; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowModerate for cancer; low for MM specificityB: companion measure or framework for FACT-MMMSAS [51]+ / Moderate for symptoms; indirect for MM+ / Low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: symptom companion measureESAS [52]+ / Low for symptom screening; indirect for MMN/AN/A+ / Low? / Very low? / Very low+ / Low+ / LowLowB: symptom screening onlyMSAS-SF [53]+ / Low for symptoms; indirect for MM+ / Low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: brief symptom companion measureEQ-5D-5 L [54, 55]+ / Moderate for generic health; indirect for MMN/AN/A+ / Low? / Very low? / Very low+ / Low? / Very lowLow for MM-specific HRQoLB: health-economic companion measure onlySF-36 [56]+ / Moderate for generic health; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowLow for MM-specific HRQoLB: generic comparator, not MM-specific+ = sufficient; − = insufficient; ? = indeterminate; N/A = not applicable. Certainty ratings are expressed as result/certainty. Recommendation A = sufficient content validity + at least low‑quality evidence for sufficient internal consistency; B = promising but requires further validation Table 4Summary of measurement-property evidence and COSMIN recommendationsPROMContent validityStructural validityInternal consistencyReliabilityMeasurement errorCriterion validityConstruct validity / hypothesis testingResponsivenessOverall certaintyRecommendationEORTC QLQ-MY20 [32–38]+ / Low+ / Low–Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low–Moderate+ / LowLow–ModerateA: strongest current MM-specific option, but update content validity and change metricsMyPOS [39–41]+ / Moderate+ / Low+ / Low–Moderate+ / Low? / Very low? / Very low+ / Low+ / LowLow–ModerateA: suitable when broad patient concerns and palliative-care needs are centralFACT-MM [42]+ / Low? / Very low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: promising but needs independent structural, reliability, and responsiveness evidenceMDASI-MM [43, 44]+ / Low–Moderate+ / Low+ / Low–Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: appropriate for MM symptom burden, not stand-alone HRQoLMySIm-Q [45]+ / Moderate+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: useful for symptom-impact endpoints; further independent validation and change-metric studies neededQLICP-MM [18]? / Low+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low+ / LowLowB: potentially useful in Chinese contexts; cross-cultural evidence neededHM-PRO [46–48]+ / Low–Moderate+ / Low+ / Low+ / Low? / Very low? / Very low+ / Low? / Very lowLowB: useful for hematological malignancies; MM-specific evidence indirectEORTC QLQ-C30 [49]+ / Moderate for cancer; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low+ / LowModerate for cancer; low for MM specificityB: companion measure; not sufficient alone for MM-specific HRQoLFACT-G [50]+ / Moderate for cancer; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowModerate for cancer; low for MM specificityB: companion measure or framework for FACT-MMMSAS [51]+ / Moderate for symptoms; indirect for MM+ / Low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: symptom companion measureESAS [52]+ / Low for symptom screening; indirect for MMN/AN/A+ / Low? / Very low? / Very low+ / Low+ / LowLowB: symptom screening onlyMSAS-SF [53]+ / Low for symptoms; indirect for MM+ / Low+ / Low? / Very low? / Very low? / Very low+ / Low? / Very lowLowB: brief symptom companion measureEQ-5D-5 L [54, 55]+ / Moderate for generic health; indirect for MMN/AN/A+ / Low? / Very low? / Very low+ / Low? / Very lowLow for MM-specific HRQoLB: health-economic companion measure onlySF-36 [56]+ / Moderate for generic health; indirect for MM+ / Moderate+ / Moderate+ / Low? / Very low? / Very low+ / Low? / Very lowLow for MM-specific HRQoLB: generic comparator, not MM-specific+ = sufficient; − = insufficient; ? = indeterminate; N/A = not applicable. Certainty ratings are expressed as result/certainty. Recommendation A = sufficient content validity + at least low‑quality evidence for sufficient internal consistency; B = promising but requires further validation Summary of measurement-property evidence and COSMIN recommendations + = sufficient; − = insufficient; ? = indeterminate; N/A = not applicable. Certainty ratings are expressed as result/certainty. Recommendation A = sufficient content validity + at least low‑quality evidence for sufficient internal consistency; B = promising but requires further validation Table 5Practical interpretation and feasibility of included PROMsPROMStrengthsLimitationsBest suited forUse recommendationEORTC QLQ-MY20Most widely evaluated MM-specific module; compatible with EORTC QLQ-C30; international useOlder development evidence; limited measurement error and contemporary content validationMM-specific HRQoL in trials and observational studiesPreferred MM-specific HRQoL module when EORTC framework is usedMyPOSPatient-centered; broad coverage of symptoms, emotional concerns, practical issues, and palliative-care needsLess widely used than QLQ-MY20; measurement error limitedClinical and palliative-care MM researchStrong option when comprehensive patient concerns are centralFACT-MMBuilt on FACIT/FACT-G framework; MM-specific moduleLess evidence for structural validity and responsivenessStudies already using FACT instrumentsUse when FACIT compatibility is needed; collect additional validation dataMDASI-MMBrief symptom-severity and interference measure; intuitive numeric ratingsSymptom-focused and not comprehensive HRQoLSymptom burden, treatment toxicity, clinical monitoringUse as symptom endpoint or companion measureMySIm-QDeveloped for MM symptoms and impacts; patient-centered symptom-impact focusIndependent validation and interpretability/MIC evidence remain limitedSymptom-impact endpoints in trialsPromising; further validation recommendedQLICP-MMDesigned for Chinese MM population; disease-specific moduleLimited international evidence and cross-cultural validationChinese-language HRQoL studiesUse in Chinese contexts; expand validationHM-PROHematology-specific broad instrument; includes symptoms and impactsNot MM-specific; MM subgroup evidence may be indirectHematological malignancy studies including MMUse when cross-hematology comparison is desiredEORTC QLQ-C30Established cancer HRQoL core instrument; compatible with QLQ-MY20Not MM-specificCore cancer HRQoL companion measureUse with QLQ-MY20 rather than aloneFACT-GEstablished cancer HRQoL core instrument; compatible with FACT-MMNot MM-specificFACIT/FACT framework studiesUse with FACT-MM rather than aloneMSAS/MSAS-SFCaptures multidimensional symptom burdenNot MM-specific; not HRQoL comprehensiveBroad symptom assessmentUse as symptom companion measureESASVery brief symptom screening; feasible in clinical settingsLimited domains; screening rather than comprehensive measurementRoutine symptom screeningUse for screening, not primary HRQoL endpointEQ-5D-5 LUtility scores for cost-effectiveness; low burdenMajor content gaps for MM-specific symptomsEconomic evaluation and cross-disease comparisonUse only as companion utility measureSF-36Broad generic health profile; cross-condition comparisonLimited MM-specific sensitivityGeneral health comparisonUse as generic comparator, not stand-alone MM HRQoL measureThis table supports clinical and research selection but does not replace the COSMIN evidence ratings in Table 4 Table 5Practical interpretation and feasibility of included PROMsPROMStrengthsLimitationsBest suited forUse recommendationEORTC QLQ-MY20Most widely evaluated MM-specific module; compatible with EORTC QLQ-C30; international useOlder development evidence; limited measurement error and contemporary content validationMM-specific HRQoL in trials and observational studiesPreferred MM-specific HRQoL module when EORTC framework is usedMyPOSPatient-centered; broad coverage of symptoms, emotional concerns, practical issues, and palliative-care needsLess widely used than QLQ-MY20; measurement error limitedClinical and palliative-care MM researchStrong option when comprehensive patient concerns are centralFACT-MMBuilt on FACIT/FACT-G framework; MM-specific moduleLess evidence for structural validity and responsivenessStudies already using FACT instrumentsUse when FACIT compatibility is needed; collect additional validation dataMDASI-MMBrief symptom-severity and interference measure; intuitive numeric ratingsSymptom-focused and not comprehensive HRQoLSymptom burden, treatment toxicity, clinical monitoringUse as symptom endpoint or companion measureMySIm-QDeveloped for MM symptoms and impacts; patient-centered symptom-impact focusIndependent validation and interpretability/MIC evidence remain limitedSymptom-impact endpoints in trialsPromising; further validation recommendedQLICP-MMDesigned for Chinese MM population; disease-specific moduleLimited international evidence and cross-cultural validationChinese-language HRQoL studiesUse in Chinese contexts; expand validationHM-PROHematology-specific broad instrument; includes symptoms and impactsNot MM-specific; MM subgroup evidence may be indirectHematological malignancy studies including MMUse when cross-hematology comparison is desiredEORTC QLQ-C30Established cancer HRQoL core instrument; compatible with QLQ-MY20Not MM-specificCore cancer HRQoL companion measureUse with QLQ-MY20 rather than aloneFACT-GEstablished cancer HRQoL core instrument; compatible with FACT-MMNot MM-specificFACIT/FACT framework studiesUse with FACT-MM rather than aloneMSAS/MSAS-SFCaptures multidimensional symptom burdenNot MM-specific; not HRQoL comprehensiveBroad symptom assessmentUse as symptom companion measureESASVery brief symptom screening; feasible in clinical settingsLimited domains; screening rather than comprehensive measurementRoutine symptom screeningUse for screening, not primary HRQoL endpointEQ-5D-5 LUtility scores for cost-effectiveness; low burdenMajor content gaps for MM-specific symptomsEconomic evaluation and cross-disease comparisonUse only as companion utility measureSF-36Broad generic health profile; cross-condition comparisonLimited MM-specific sensitivityGeneral health comparisonUse as generic comparator, not stand-alone MM HRQoL measureThis table supports clinical and research selection but does not replace the COSMIN evidence ratings in Table 4 Practical interpretation and feasibility of included PROMs This table supports clinical and research selection but does not replace the COSMIN evidence ratings in Table 4 Table 6Final recommended PROM selection framework for MM research and clinical assessmentRank/roleRecommended PROM(s)RationaleImportant caveatPrimary MM-specific HRQoL assessmentEORTC QLQ-MY20 + EORTC QLQ-C30Broadest MM-specific evidence base; international use; compatible oncology core questionnaireUpdate content validity and change metrics are still neededBroad patient concerns and palliative-care needsMyPOSPatient-centered coverage of symptoms, emotional, practical, informational, and care-related concernsLess evidence than QLQ-MY20 in some psychometric domainsSymptom-burden endpointMDASI-MM; MySIm-QDesigned to capture MM symptom severity, interference, and symptom impactsNot sufficient for comprehensive HRQoL aloneChinese-language MM-specific HRQoLQLICP-MM; Chinese QLQ-MY20; Chinese MDASI-MMAvailable Chinese-language options with supportive evidenceCross-cultural comparability and measurement invariance require further testingHematological malignancy comparisonHM-PROUseful when MM is studied alongside other hematologic malignanciesMM-specific content may be less complete than disease-specific instrumentsHealth-economic or cross-disease comparisonEQ-5D-5 L; SF-36Provide utility or generic health estimatesShould be companion measures only when MM-specific HRQoL is the main constructFinal selection should also consider respondent burden, licensing, language availability, scoring requirements, target construct, and whether the study requires disease-specific or generic comparability Table 6Final recommended PROM selection framework for MM research and clinical assessmentRank/roleRecommended PROM(s)RationaleImportant caveatPrimary MM-specific HRQoL assessmentEORTC QLQ-MY20 + EORTC QLQ-C30Broadest MM-specific evidence base; international use; compatible oncology core questionnaireUpdate content validity and change metrics are still neededBroad patient concerns and palliative-care needsMyPOSPatient-centered coverage of symptoms, emotional, practical, informational, and care-related concernsLess evidence than QLQ-MY20 in some psychometric domainsSymptom-burden endpointMDASI-MM; MySIm-QDesigned to capture MM symptom severity, interference, and symptom impactsNot sufficient for comprehensive HRQoL aloneChinese-language MM-specific HRQoLQLICP-MM; Chinese QLQ-MY20; Chinese MDASI-MMAvailable Chinese-language options with supportive evidenceCross-cultural comparability and measurement invariance require further testingHematological malignancy comparisonHM-PROUseful when MM is studied alongside other hematologic malignanciesMM-specific content may be less complete than disease-specific instrumentsHealth-economic or cross-disease comparisonEQ-5D-5 L; SF-36Provide utility or generic health estimatesShould be companion measures only when MM-specific HRQoL is the main constructFinal selection should also consider respondent burden, licensing, language availability, scoring requirements, target construct, and whether the study requires disease-specific or generic comparability Final recommended PROM selection framework for MM research and clinical assessment Final selection should also consider respondent burden, licensing, language availability, scoring requirements, target construct, and whether the study requires disease-specific or generic comparability Table 7Final recommendation for each PROMPROMRecommendation classBasis for recommendationSuggested useKey caveats/evidence gapsQLQ-MY20ASufficient content validity and moderate-certainty evidence for internal consistency; additional supportive evidence was available for reliability, hypothesis testing for construct validity, and responsiveness.Preferred disease-specific module for MM HRQoL assessment, especially in trials or studies using the EORTC systemMust be administered with QLQ-C30 core questionnaire; evidence gaps remain for measurement error and formal measurement invarianceMyPOSAModerate-certainty evidence supported content validity, and low-to-moderate evidence supported internal consistency; reliability, hypothesis testing for construct validity, and responsiveness were also supported by low-certainty evidence.Suitable for routine clinical monitoring and supportive-care-oriented assessment in MMHealthcare Support subscale and floor effects require attention; measurement error evidence lackingMDASI-MMBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but evidence for measurement error, criterion validity, and responsiveness remained limited or indeterminate.Appropriate when the primary purpose is symptom burden and symptom interference assessmentNot a full HRQoL instrument; measurement error and cross-cultural/MI evidence remain limitedHM-PROBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but the evidence was partly indirect because HM-PRO is hematology-specific rather than MM-specific.Can be considered when a generic hematologic malignancy PROM is neededImportant indirectness (evidence from hematological malignancies, not MM-specific); MM‑specific subgroup evidence should be strengthened.FACT-GBA core cancer PROM with supportive evidence for structural validity, internal consistency, reliability, and hypothesis testing for construct validity, although content validity evidence was indirect for MM-specific HRQoL.Useful for general cancer HRQoL comparison, especially alongside disease-specific modulesIndirectness for MM (evidence from general cancer populations); does not cover myeloma‑specific issues alone.FACT-MMBLow-certainty evidence supported content validity, internal consistency, and hypothesis testing for construct validity, whereas evidence for structural validity, reliability, measurement error, criterion validity, and responsiveness remained limited or indeterminate.Promising MM-specific module; may be used when FACT system is requiredNeeds independent validation in larger MM samples, particularly for structural validity, reliability, measurement error, responsiveness, and interpretability.MySIm-QBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but evidence for measurement error, criterion validity, responsiveness, and interpretability/MIC remained limited or indeterminate.Promising instrument for active MM symptom/impact measurement in trialsFurther studies are needed to examine measurement error, responsiveness, criterion validity where appropriate, and interpretability/MIC.QLICP-MMBContent validity was partly indeterminate, whereas structural validity, internal consistency, reliability, hypothesis testing for construct validity, and responsiveness showed supportive but low-certainty evidence.Potentially useful in Chinese MM populationsCannot receive A-level until content-validity evidence is clarified and broader cross-cultural and measurement-error evidence becomes available.QLQ-C30BA core cancer PROM with supportive evidence for structural validity, internal consistency, reliability, hypothesis testing for construct validity, and responsiveness, although content validity evidence was indirect for MM-specific HRQoL.Should be used as the EORTC core questionnaire with QLQ-MY20B reflects review evidence, not global legacy evidenceMSASBContent validity for cancer symptoms was indirect for MM; structural validity, internal consistency, and hypothesis testing for construct validity showed low-certainty support, whereas reliability, measurement error, and responsiveness remained limited or indeterminate.Use for multidimensional symptom assessment rather than HRQoL aloneNot MM-specific; content validity and measurement error gaps remainESASBBrief symptom-screening measure with supportive reliability, hypothesis-testing, and responsiveness evidence in cancer or palliative-care populations; internal consistency and structural validity were not treated as primary criteria for this item-level symptom tool.Useful for rapid symptom screeningComposite symptom tool; internal consistency/structural validity should be interpreted cautiouslyMSAS-SFBA brief symptom instrument with low-certainty evidence supporting structural validity, internal consistency, and hypothesis testing for construct validity; reliability, measurement error, and responsiveness remained limited or indeterminate.Use where a shorter symptom burden tool is neededNot MM-specific; content validity and measurement error gaps remainEQ-5D-5 LBContent validity and reliability were supported for generic/preference-based use, and hypothesis testing for construct validity showed low-certainty support; structural validity and internal consistency were not treated as applicable.Useful when health utility or economic evaluation is neededPreference-based formative/composite instrument; use COSMIN reflective criteria cautiouslySF-36BGeneric legacy measure with supportive evidence for structural validity, internal consistency, reliability, and hypothesis testing for construct validity, but content validity evidence was indirect for MM-specific HRQoL.Use for broad generic health status comparisonsB reflects MM-focused evidence base; global legacy evidence may be underestimatedA = PROMs that can be recommended for use; B = PROMs with potential use but requiring further validation Table 7Final recommendation for each PROMPROMRecommendation classBasis for recommendationSuggested useKey caveats/evidence gapsQLQ-MY20ASufficient content validity and moderate-certainty evidence for internal consistency; additional supportive evidence was available for reliability, hypothesis testing for construct validity, and responsiveness.Preferred disease-specific module for MM HRQoL assessment, especially in trials or studies using the EORTC systemMust be administered with QLQ-C30 core questionnaire; evidence gaps remain for measurement error and formal measurement invarianceMyPOSAModerate-certainty evidence supported content validity, and low-to-moderate evidence supported internal consistency; reliability, hypothesis testing for construct validity, and responsiveness were also supported by low-certainty evidence.Suitable for routine clinical monitoring and supportive-care-oriented assessment in MMHealthcare Support subscale and floor effects require attention; measurement error evidence lackingMDASI-MMBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but evidence for measurement error, criterion validity, and responsiveness remained limited or indeterminate.Appropriate when the primary purpose is symptom burden and symptom interference assessmentNot a full HRQoL instrument; measurement error and cross-cultural/MI evidence remain limitedHM-PROBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but the evidence was partly indirect because HM-PRO is hematology-specific rather than MM-specific.Can be considered when a generic hematologic malignancy PROM is neededImportant indirectness (evidence from hematological malignancies, not MM-specific); MM‑specific subgroup evidence should be strengthened.FACT-GBA core cancer PROM with supportive evidence for structural validity, internal consistency, reliability, and hypothesis testing for construct validity, although content validity evidence was indirect for MM-specific HRQoL.Useful for general cancer HRQoL comparison, especially alongside disease-specific modulesIndirectness for MM (evidence from general cancer populations); does not cover myeloma‑specific issues alone.FACT-MMBLow-certainty evidence supported content validity, internal consistency, and hypothesis testing for construct validity, whereas evidence for structural validity, reliability, measurement error, criterion validity, and responsiveness remained limited or indeterminate.Promising MM-specific module; may be used when FACT system is requiredNeeds independent validation in larger MM samples, particularly for structural validity, reliability, measurement error, responsiveness, and interpretability.MySIm-QBContent validity, structural validity, internal consistency, reliability, and hypothesis testing for construct validity were supported, but evidence for measurement error, criterion validity, responsiveness, and interpretability/MIC remained limited or indeterminate.Promising instrument for active MM symptom/impact measurement in trialsFurther studies are needed to examine measurement error, responsiveness, criterion validity where appropriate, and interpretability/MIC.QLICP-MMBContent validity was partly indeterminate, whereas structural validity, internal consistency, reliability, hypothesis testing for construct validity, and responsiveness showed supportive but low-certainty evidence.Potentially useful in Chinese MM populationsCannot receive A-level until content-validity evidence is clarified and broader cross-cultural and measurement-error evidence becomes available.QLQ-C30BA core cancer PROM with supportive evidence for structural validity, internal consistency, reliability, hypothesis testing for construct validity, and responsiveness, although content validity evidence was indirect for MM-specific HRQoL.Should be used as the EORTC core questionnaire with QLQ-MY20B reflects review evidence, not global legacy evidenceMSASBContent validity for cancer symptoms was indirect for MM; structural validity, internal consistency, and hypothesis testing for construct validity showed low-certainty support, whereas reliability, measurement error, and responsiveness remained limited or indeterminate.Use for multidimensional symptom assessment rather than HRQoL aloneNot MM-specific; content validity and measurement error gaps remainESASBBrief symptom-screening measure with supportive reliability, hypothesis-testing, and responsiveness evidence in cancer or palliative-care populations; internal consistency and structural validity were not treated as primary criteria for this item-level symptom tool.Useful for rapid symptom screeningComposite symptom tool; internal consistency/structural validity should be interpreted cautiouslyMSAS-SFBA brief symptom instrument with low-certainty evidence supporting structural validity, internal consistency, and hypothesis testing for construct validity; reliability, measurement error, and responsiveness remained limited or indeterminate.Use where a shorter symptom burden tool is neededNot MM-specific; content validity and measurement error gaps remainEQ-5D-5 LBContent validity and reliability were supported for generic/preference-based use, and hypothesis testing for construct validity showed low-certainty support; structural validity and internal consistency were not treated as applicable.Useful when health utility or economic evaluation is neededPreference-based formative/composite instrument; use COSMIN reflective criteria cautiouslySF-36BGeneric legacy measure with supportive evidence for structural validity, internal consistency, reliability, and hypothesis testing for construct validity, but content validity evidence was indirect for MM-specific HRQoL.Use for broad generic health status comparisonsB reflects MM-focused evidence base; global legacy evidence may be underestimatedA = PROMs that can be recommended for use; B = PROMs with potential use but requiring further validation Final recommendation for each PROM A = PROMs that can be recommended for use; B = PROMs with potential use but requiring further validation Discussion Main findings This COSMIN-based systematic review identified a heterogeneous body of evidence for PROMs used to assess HRQoL, symptoms, and disease burden in MM. The findings suggest that several MM-specific or MM-relevant instruments are available, but the psychometric evidence base is uneven across measurement properties. Most validation studies focused on internal consistency, structural validity, and construct validity, whereas content validity, measurement error, cross-cultural validity, interpretability, and responsiveness were less frequently and less rigorously addressed. A central finding is that instrument specificity matters. PROMs developed for MM or hematological malignancies were more likely to cover symptoms and impacts that are highly salient to patients with MM, such as bone pain, fatigue, treatment-related adverse effects, uncertainty about the future, and disease-specific functional limitations. However, disease specificity alone should not be interpreted as sufficient psychometric evidence. According to COSMIN, content validity requires explicit evidence that items are relevant, comprehensive, and comprehensible to the target population. Therefore, instruments with strong clinical uptake, such as the EORTC QLQ-MY20, still benefit from updated content-validation work, particularly because MM treatment pathways and survivorship experiences have changed substantially over time. The EORTC QLQ-MY20 emerged as the most extensively studied MM-specific module. Its major strengths are broad international use, compatibility with the EORTC QLQ-C30, and supportive evidence for several measurement properties. This makes it a defensible option for MM clinical trials and observational studies, especially when comparison with oncology HRQoL data is needed. MyPOS also demonstrated a relatively broad evidence base and may be particularly useful in settings where symptom burden, palliative-care concerns, emotional distress, information needs, and practical problems are all important. MDASI-MM and MySIm-Q provide more symptom-focused alternatives, while FACT-MM and QLICP-MM may be useful depending on the study context, language, and scoring infrastructure. A second important finding is that several key COSMIN domains remain underdeveloped. Measurement-error evidence was rarely reported, which limits interpretation of individual-level change and the ability to distinguish true change from random variation. Responsiveness evidence was also limited and often lacked prespecified hypotheses or anchor-based thresholds. Cross-cultural validity and measurement invariance were seldom tested, even when translated versions of instruments were used. These gaps are especially important in MM research because international trials, multinational registries, and cross-cultural survivorship studies increasingly rely on harmonized PROM data. The results also clarify the role of generic instruments. EQ-5D-5 L and SF-36 are useful for economic evaluation, burden-of-disease comparisons, and cross-condition benchmarking. Nevertheless, their content validity for MM-specific HRQoL is limited because they do not fully capture symptoms, treatment toxicities, and psychosocial concerns that are central to MM patients. Therefore, they should be used as companion measures rather than substitutes for MM-specific PROMs when the primary outcome is MM-related HRQoL. Psychometric properties Although various instruments are available for precise measurement of QoL in MM patients, most PROMs included in this review lack comprehensive evidence across a range of psychometric properties. Content validity is the most crucial measurement property for PROMs, reflecting the degree to which an instrument’s content adequately represents the construct it intends to measure [31]. In this systematic review, most studies focused on relevance and comprehensibility, interviewing experts and/or patients, but few conducted formal expert consultation, and comprehensiveness was often neglected. The assessment of content validity can be based on either qualitative methods (e.g., interviews, cognitive interviews) or quantitative methods (e.g., importance ratings), each of which has its own value. Among the studies included in this review, some employed mixed methods while others used only a single method; this does not constitute a methodological flaw. Therefore, future studies must employ more rigorous and transparent methods (e.g., conducting adequate cognitive interviews with detailed reporting) to re-evaluate the content validity of existing tools. Structural validity assesses whether a tool measures the intended dimensions. Results showed variable methodological quality. Confirmatory Factor Analysis (CFA), a superior method for validating hypothesized structures [57], was used in only 4 studies [35, 40, 44, 48], while more studies employed Exploratory Factor Analysis (EFA) or Principal Component Analysis (PCA). Multiple EFA/PCA studies were rated “insufficient” (-) due to a high number of cross-loadings (> 10% of items loading ≥ 0.30 on multiple factors), suggesting unclear internal structure or multidimensionality, potentially affecting interpretative accuracy. Therefore, instruments with poor results from EFA/PCA (e.g., FACT-MM, MySIm-Q) require further validation using CFA in independent samples. Advanced methods like Rasch analysis or confirmatory bifactor models should be used to examine unidimensionality, providing a more solid basis for assessing internal consistency [58, 59]. Internal consistency is a key indicator of the homogeneity among items within a tool [27]. In this review, most studies assessed this property, with generally good methodological quality and sufficient measurement properties, indicating these instruments have acceptable internal reliability at the total or subscale level. Test-retest reliability assesses score stability over time. Ten studies [18, 35, 36, 38, 40, 50, 52, 53, 55, 56] evaluated this, but half lacked a theoretical basis for retest interval selection (too short or unspecified), and others failed to ensure stable patient health status or consistent conditions between tests, potentially leading to over- or underestimation of reliability [60]. COSMIN guidelines suggest a suitable retest interval for relatively stable constructs like QoL is typically 2–4 weeks [61]. Future reliability studies should design retest procedures rigorously, specify the interval clearly, and assess and report the conditions and patient status at retest. Hypothesis testing is a core method for assessing the construct validity of PROMs [25]. In this review, 16 studies [18, 32–34, 36, 37, 39, 43, 44, 47, 50–53, 55, 56] provided supportive evidence through hypothesis testing, including correlations with related constructs and comparisons between clinically distinct groups. Most of these studies reported that PROM scores differed in expected directions across groups defined by disease status, treatment phase, performance status, or symptom burden, providing supportive known-groups evidence. In COSMIN terminology, known-groups comparisons are best interpreted as one form of hypothesis testing for construct validity rather than as discriminant validity. Discriminant validity, in contrast, refers to evidence that PROM scores are not strongly associated with measures of different constructs. However, three studies [18, 44, 47] did not report subgroup comparisons. This reporting gap limits the interpretation of whether these instruments can distinguish clinically meaningful patient groups in real-world MM settings [27]. Insufficient known-groups evidence may also reduce the practical value of a PROM for guiding individualized treatment decisions or identifying high-risk patient groups [62]. Future studies should predefine hypothesis-testing criteria, including expected directions and magnitudes of correlations or group differences, and should select clinically meaningful contrast groups such as newly diagnosed versus relapsed/refractory patients or patients with different treatment responses [63]. Responsiveness is crucial for monitoring patient change over time and for evaluating treatment effects in clinical trials and longitudinal studies [64]. Responsiveness evidence was reported less frequently than internal consistency and construct validity. Where available, responsiveness evidence was mostly supportive, but the certainty remained low because longitudinal hypotheses, stable anchors, and anchor-based interpretability thresholds were often incompletely specified. With the rapid evolution of MM treatments, more longitudinal studies are needed. Future studies should employ anchor-based methods, such as the Patient Global Impression of Change, and distribution-based methods where appropriate; predefine hypotheses regarding expected score changes; and estimate or prespecify minimal important change values to evaluate whether PROMs can detect true change over time. Such evidence would help determine PROM sensitivity to treatment response, disease relapse, or symptom worsening [65]. Cross-cultural validity, measurement-error evidence, and criterion validity: underreported dimensions This review found no included studies that formally assessed cross-cultural validity or measurement invariance. Most cross-cultural studies were limited to translation and linguistic adaptation and did not statistically test measurement equivalence, such as factor structure, item functioning, or differential item functioning [66, 67]. Similarly, no included study provided a formal COSMIN-based evaluation of measurement error using indices such as the standard error of measurement, smallest detectable change, limits of agreement, or comparison with a minimal important change. This lack of measurement-error evidence limits interpretation of individual-level score changes, because it remains difficult to determine whether an observed change reflects true change rather than random measurement variation [68]. Regarding criterion validity, we acknowledge that for most HRQoL PRO measures, no true gold standard exists [69]. Objective clinical outcomes, such as progression-free survival or laboratory biomarkers, should not be automatically treated as criteria for patient-reported HRQoL. Instead, they may serve as external clinical anchors or known-group variables only when a clear theoretical rationale links them to the PRO construct [70]. In the absence of both a gold standard and theory-grounded anchors, traditional criterion validity could not be meaningfully assessed in the reviewed studies. Future validation efforts should strengthen hypothesis-testing evidence, including known-groups comparisons, convergent validity, and discriminant validity when appropriate measures of dissimilar constructs are available, and should examine associations with relevant clinical endpoints only as supporting evidence when theoretically justified [27]. Implications for clinical practice Multiple myeloma and its treatment impose a persistent and multidimensional burden on patients’ physical function, psychological state, and overall quality of life. Therefore, systematic and precise assessment of patient-reported outcomes is crucial for implementing individualized support, optimizing symptom management, and enhancing overall care quality. Based on the synthesized evidence from this systematic review following COSMIN guidelines, we suggest clinicians and researchers prioritize instruments with an A-level recommendation based on specific assessment purposes. For MM-specific HRQoL assessment, the EORTC QLQ-MY20 (used with the QLQ-C30) and MyPOS are the current A-level options. For symptom-focused purposes, B-level instruments such as MDASI-MM may be considered, but they require further validation. However, no single instrument is superior in all measurement properties. In clinical practice, factors such as completion time, patient burden, and the availability of validated localized language versions must also be weighed when selecting an instrument. Limitations and future directions This study followed PRISMA-COSMIN guidelines [27], involved two independent reviewers, and used updated COSMIN standards for evidence grading and synthesis, yielding reliable conclusions. However, limitations include the near-universal absence of evidence for cross-cultural validity. This implies that although the QLQ-MY20 received an A-level recommendation in this review, its version in China or non-English-speaking countries may not have undergone rigorous measurement invariance testing (e.g., DIF analysis); thus, cross-country comparative data should be interpreted cautiously. Limiting the search to English and Chinese literature may have missed important validation studies from Europe (e.g., in German, French) on EORTC instruments. Incomplete reporting in some original studies affected methodological quality ratings. Grey literature (e.g., unpublished pharmaceutical industry reports) was not searched, potentially introducing publication bias. Downgrading for “indirectness” in evidence grading reflects that some instruments were not specifically developed for MM. While this aligns with COSMIN standards, it also suggests the application value of generic instruments in specific populations needs to be considered alongside clinical judgment. Furthermore, this review only included psychometric validation studies conducted in patients with multiple myeloma. Therefore, a substantial body of evidence on measurement properties (particularly cross-cultural equivalence and longitudinal measurement invariance) for generic or cross-cancer instruments such as the SF-36, EORTC QLQ-C30, and FACT-G, which was accumulated in other populations (e.g., other cancers, chronic diseases), was not included. This may lead to an underestimation of the overall performance of these instruments. Future MM studies should make reference to this existing evidence base whenever possible. Based on the above discussion, future research should: Prioritize high-quality cross-cultural validation: Systematic assessment of measurement invariance is essential when introducing an instrument into a new cultural context [71]. Adopt longitudinal designs: To comprehensively evaluate responsiveness, measurement error, and long-term reliability. Enhance methodological rigor: When using PROMs developed under a reflective measurement model, it is recommended to follow the COSMIN guidelines to improve study quality and comparability; for formative or composite measurement tools, applicable items should be selected with caution, and other methodological frameworks (such as specific criteria for health utility instruments) should be supplemented. Explore electronic migration: With the growing use of telemedicine in hematology management, validating the equivalence of migrating instruments from paper to electronic formats (apps, web-based) is a new focus. This review found very few studies specifically assessing the usability of electronic versions in the MM population. Future research should focus on the user experience (UI/UX) and feasibility of data collection for ePROMs, and assess measurement equivalence between paper-based PROMs and ePROMs to leverage the advantages of digital health [72]. Focus on clinical utility: In validation studies, combine anchor-based methods to determine thresholds for clinically meaningful change, facilitating the translation of research findings into clinical decision-making [73]. Conclusion The available evidence indicates that PROM selection in MM should be guided by the intended construct, study purpose, target population, and COSMIN-based evidence profile. The EORTC QLQ-MY20 currently has the broadest international evidence base for MM-specific HRQoL assessment, particularly when combined with the EORTC QLQ-C30. MyPOS is also well suited for capturing broad patient concerns and palliative-care needs. Symptom-focused measures such as MDASI-MM and MySIm-Q may be appropriate when symptom burden is the primary endpoint. Generic instruments remain valuable as companion measures but are insufficient as stand-alone instruments for MM-specific HRQoL. Further high-quality studies are needed to strengthen evidence for content validity, measurement error, cross-cultural validity, responsiveness, and interpretability. Supplementary Information Supplementary Material 1. Supplementary Material 1.